Stomatitis

• 

  Subject Areas on Research

  • A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. 
  • Adriamycin in the treatment of childhood acute leukemia. A Southwest Oncology Group study. 
  • Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. 
  • Clinical use of oral contraceptives administered vaginally: a case report. 
  • Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers. 
  • Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. 
  • Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. 
  • Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. 
  • Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. 
  • MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. 
  • Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. 
  • NCCN Task Force Report. prevention and management of mucositis in cancer care. 
  • Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model. 
  • Oral manifestations of chronic graft-v-host disease. 
  • Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. 
  • Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. 
  • Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. 
  • Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. 
  • Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. 
  • Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.